Highly positive FM71 Phase 3 Study Results with all primary and secondary endpoints achieved, MED3000 remains on track to obtain US FDA marketing authorisation
Futura Medical PLC (AIM:FUM) MED3000 Collaboration in EEA, UK & Switzerland
Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland
OKYO Pharma LTD (OKYO.L) Announces final audited results for the year ended 31 March 2021
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.
Green light for small cell lung cancer treatment given to AstraZeneca in China
Based on positive results in a phase III trial, Imfinzi demonstrated improvement over chemotherapy alone, the approval was granted
OKYO Pharma Limited (OKYO.L) Regulatory Development of OK-101 for Dry Eye Indications
London and Boston, MA, 29 June 2021 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory
Sareum Holdings PLC (SAR.L) Subscription to raise £900,000
Subscription to raise £900,000 to progress proprietary TYK2/JAK1 programmes through final stages of preclinical development
Physiomics PLC (PYC.L) Conference presentation
Physiomics to present on Personalized Medicine and Virtual Tumour at AACR 2021 Annual Meeting
TPI provides its latest research note on DeepVerge plc (DVRG.L).
Deepverge has confirmed receipt of contractual orders to the value of US$5m (£3.6m*) for Modern Water equipment so far in Q1 2021, including eight of its units being retrofitted with
TPI provides its latest research note on Microsaic Systems plc (MSYS.L) and DeepVerge plc (DVRG.L).
Microsaic has signed a non-binding Heads of Terms (‘HoT’) with Deepverge to enter a multi-year Framework Services Agreement (‘Agreement’), which is expected to be signed on or before 31 March
Tiziana Life Sciences (TILS.L) Gabriele Cerrone, Founder & Chairman Interview
It has been a boom time in the pharmaceutical sector, yesterday Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses.